today announced that the Cystic Fibrosis Foundation has made an up to USD $2.3 million equity investment (circa £1.7 million) in Owlstone to develop a breath test for Pseudomonas aeruginosa (PA ...

The winners of this year’s Canadian science prizes are all based in the United States, where Trump-era cutbacks to research ...

Statement this week stirred commentary from business figures in the M&A market, who looked at how the deal sector may be impacted going forward. In light of ...

The Foundation’s funding will support Owlstone Medical’s development of a breath test to help doctors diagnose and monitor Pseudomonas aeruginosa infections in people with cystic fibrosis. The Cystic ...

inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa – P.a. or P. aeruginosa – infections in non-cystic fibrosis bronchiectasis, or NCFB, patients.

NEW YORK – Owlstone Medical announced Tuesday that the Cystic Fibrosis Foundation has made an equity ... The investment supports development of a breath-based assay for Pseudomonas aeruginosa, a ...

The Cystic Fibrosis (CF) Foundation announced today that it has ... study on the feasibility of analyzing breath to detect lung infections caused by Pseudomonas aeruginosa, a frequently ...

Rationale The most common antibiotic used to treat people with cystic fibrosis (PWCF) is inhaled tobramycin, administered as maintenance therapy for chronic Pseudomonas aeruginosa lung infections.